Kiyoshi Migita1, Yasumori Izumi2, Keita Fujikawa2, Kazunaga Agematsu2, Junya Masumoto2, Yuka Jiuchi2, Hideko Kozuru2, Fumiaki Nonaka2, Toshimasa Shimizu2, Tadashi Nakamura2, Nozomi Iwanaga2, Hiroshi Furukawa2, Michio Yasunami2, Atsushi Kawakami2, Katsumi Eguchi2. 1. Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehime University Graduate School of Medicine and Proteo-Science Center, Ehime, Department of Rheumatology, Sasebo City General Hospital, Sasebo, Department of Rheumatology, Shinto Kumamoto Hospital, Kumamoto, Clinical Research Center, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Institute of Tropical Medicine (NEKKEN), Nagasaki University and Department of Rheumatology, Nagasaki University Hospital, Nagasaki, Japan. migita@nagasaki-mc.com. 2. Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Department of Rheumatology, Isahaya Health Insurance General Hospital, Nagasaki, Department of Infection and Host Defense, Graduate School of Medicine, Shinshu University, Matsumoto, Department of Pathology, Ehime University Graduate School of Medicine and Proteo-Science Center, Ehime, Department of Rheumatology, Sasebo City General Hospital, Sasebo, Department of Rheumatology, Shinto Kumamoto Hospital, Kumamoto, Clinical Research Center, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Institute of Tropical Medicine (NEKKEN), Nagasaki University and Department of Rheumatology, Nagasaki University Hospital, Nagasaki, Japan.
Abstract
OBJECTIVE: The aim of this study was to analyse the role of circulating cleaved IL-1β in patients with FMF. METHODS: We enrolled 20 patients with FMF (5 males and 15 females), 22 patients with RA (4 males and 18 females) and 22 healthy controls (6 males and 16 females). Serum levels of serum amyloid A (SAA) were measured by ELISA. We also determined whether IL-1β was present as the cleaved form (p17) in the sera of FMF patients by immunoblotting using anti-cleaved IL-1β antibody. RESULTS: Although SAA concentrations were elevated in the sera, there was no significant difference in these concentrations between FMF patients and RA patients. Immunoblot analysis demonstrated that the cleaved form of IL-1β (p17) was present in sera from FMF patients during febrile attack periods, but not in healthy controls. Bands representing the cleaved form of IL-1β were not detected in serum from FMF patients at non-febrile attack periods or remission periods under colchicine treatment. The amounts of cleaved IL-1β (p17) were significantly higher in patients with FMF compared with those in patients with RA in the inflammatory phase. CONCLUSION: The cleaved form of IL-1β is a valuable biomarker for monitoring disease activity and response to colchicine treatment in patients with FMF. It might be useful to discriminate FMF from other non-IL-1β-mediated inflammatory disorders.
OBJECTIVE: The aim of this study was to analyse the role of circulating cleaved IL-1β in patients with FMF. METHODS: We enrolled 20 patients with FMF (5 males and 15 females), 22 patients with RA (4 males and 18 females) and 22 healthy controls (6 males and 16 females). Serum levels of serum amyloid A (SAA) were measured by ELISA. We also determined whether IL-1β was present as the cleaved form (p17) in the sera of FMFpatients by immunoblotting using anti-cleaved IL-1β antibody. RESULTS: Although SAA concentrations were elevated in the sera, there was no significant difference in these concentrations between FMFpatients and RApatients. Immunoblot analysis demonstrated that the cleaved form of IL-1β (p17) was present in sera from FMFpatients during febrile attack periods, but not in healthy controls. Bands representing the cleaved form of IL-1β were not detected in serum from FMFpatients at non-febrile attack periods or remission periods under colchicine treatment. The amounts of cleaved IL-1β (p17) were significantly higher in patients with FMF compared with those in patients with RA in the inflammatory phase. CONCLUSION: The cleaved form of IL-1β is a valuable biomarker for monitoring disease activity and response to colchicine treatment in patients with FMF. It might be useful to discriminate FMF from other non-IL-1β-mediated inflammatory disorders.
Authors: F Nonaka; K Migita; Y Jiuchi; T Shimizu; M Umeda; N Iwamoto; K Fujikawa; Y Izumi; A Mizokami; M Nakashima; Y Ueki; M Yasunami; A Kawakami; K Eguchi Journal: Clin Exp Immunol Date: 2015-03 Impact factor: 4.330